Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma
Authors:
- Wilfred LeungWLWilfred Leung
- Timothy M. PierpontTPTimothy M. Pierpont
- Suzin WebbSWSuzin Webb
- Jessica J. HaywardJHJessica J. Hayward
- Shirley MarkantSMShirley Markant
- Nicole BelcherNBNicole Belcher
- Scott D. ButlerSBScott D. Butler
- Rishi PuriRPRishi Puri
- Michael J. ByronMBMichael J. Byron
- Marta G. CastelhanoMCMarta G. Castelhano
- Giorgio InghiramiGIGiorgio Inghirami
- Andrew D. MillerAMAndrew D. Miller
Open Access
Abstract
High-grade canine B-cell lymphoma (cBCL) is a spontaneous cancer in dogs with similar pathologic features as human diffuse large B-cell lymphoma (DLBCL). The value of comparative oncology to both dogs and humans has long been recognized, but the progress in cBCL research has been hampered by a scarcity of preclinical models. This study aimed to establish and characterize novel patient-derived xenograft (PDX) and cell line models from primary cBCL tumors to address this critical gap. To this end, primary cBCL tumors from three canine patients were surgically excised and serially transplanted into immunodeficient NOD scid gamma (NSG) mice. The resulting PDX models were characterized across passages in mice using histology, flow cytometry, single-nucleotide polymorphism (SNP) genotyping, and RNA sequencing. The results show that the samples retain many of their original characteristics, even after multiple NSG passages. Cancer cells from two of the PDX lines were successfully adapted to in vitro culture, creating two new established cell lines which were then used in drug sensitivity assays. The successful generation and characterization of these cBCL PDX and cell lines provides a valuable resource for canine cancer research and associated comparative oncology approaches.Keywords
Funding Information
- American Kennel Club Canine Health Foundation (26084)
- Cornell Joan and Sanford I. Weill Medical College CTSC KL2 (1 KL2 TR002385-01)
- Canine Lymphoma Education Awareness and Research Inc.
- Leukemia and Lymphoma Society of Canada (7012-16)
- National Center for Advancing Translational Sciences (5UL1TR002384)
- Cornell Clinical and Translational Science Center
This publication has 38 references indexed in Scilit:
- Characterization of the genomic landscape of canine diffuse large B-cell lymphoma reveals recurrent H3K27M mutations linked to progression-free survivalScientific Reports, 2025
- The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implicationsLab Animal, 2022
- Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysisCritical Reviews in Oncology/Hematology, 2020
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- The LL-100 panel: 100 cell lines for blood cancer studiesScientific Reports, 2019
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesNature Medicine, 2018
- Genetic and Functional Drivers of Diffuse Large B Cell LymphomaCell, 2017
- Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphomaLeukemia Research, 2010
- Translation of new cancer treatments from pet dogs to humansNature Reviews Cancer, 2008
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000